Follow-On Biologics Face Negotiation Slalom After Scaling Mount PDUFA

Creation of an approval pathway for follow-on biologics appears probable after proponents attached placeholder language to the user fee reauthorization bill in the Senate, but the generic industry and their allies still face considerable challenges to enacting legislation they find favorable

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet